LY-01620

N/A

Report date: 2026/05/13 09:07:43

Base Information

Drug NameLY-01620

Drug Alias NameLY01620LY-01620

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsSquamous Intraepithelial Lesions of the CervixCervical Intraepithelial Neoplasia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesNanjing Jimai Biotechnology Co., Ltd.

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Jimai Biotechnology Co., Ltd.

Inactive CompaniesN/A

Active IndicationsSquamous Intraepithelial Lesions of the CervixCervical Intraepithelial Neoplasia

Inactive IndicationsN/A

Other Information

ATC CodeN/A